Shasun Pharmaceuticals is currently trading at Rs. 309.00, up by 2.65 points or 0.87% from its previous closing of Rs. 306.35 on the BSE.
The scrip opened at Rs. 304.20 and has touched a high and low of Rs. 313.00 and Rs. 295.20 respectively. So far 21660 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 391.50 on 24-Mar-2015 and a 52 week low of Rs. 134.20 on 02-Jun-2014.
Last one week high and low of the scrip stood at Rs. 334.80 and Rs. 302.55 respectively. The current market cap of the company is Rs. 1857.83 crore.
The promoters holding in the company stood at 39.49% while Institutions and Non-Institutions held 25.72% and 34.79% respectively.
Shasun Pharmaceuticals has more than doubled its net profit at Rs 22.2 crore during the fourth quarter ended March 31, 2015, against Rs 10.4 crore reported in the corresponding quarter of the previous year. This is despite 3 per cent drop in turnover at Rs 336.1 crore for the quarter from Rs 346.6 crore in the fourth quarter of 2013-14.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: